According to the ELN guidelines, patients with an NPM1 mutation in the absence of an FLT3 mutation falling into the favorable risk category should not undergo allogeneic hematopoietic cell transplant (HCT) at first remission due to the high risk of potentially fatal infection caused by immunosuppression and graft vs. host disease, which highlights the impact of NPM1 mutation on immune conditions in AML (52). The gene discussed is NPM1; the disease is acute myeloid leukemia.